We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
RPL22 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
430.4
Number of samples
141
Samples
Sample
Description
TPM
TCGA-06-5417-01A
0 years, female, white, stage:'--, alive, 155 days
1357.9
TCGA-14-0871-01A
0 years, female, white, stage:'--, dead, 880 days
1232.9
TCGA-06-2569-01A
0 years, female, black or african american, stage:'--, alive, 13 days
978.6
TCGA-41-5651-01A
0 years, female, black or african american, stage:'--, dead, 460 days
903.0
TCGA-02-2483-01A
0 years, male, asian, stage:'--, alive, 466 days
757.3
TCGA-19-5960-01A
0 years, male, white, stage:'--, dead, 455 days
750.4
TCGA-28-5216-01A
0 years, male, white, stage:'--, alive, 415 days
710.7
TCGA-26-5133-01A
0 years, male, white, stage:'--, alive, 452 days
707.8
TCGA-19-4065-01A
0 years, male, white, stage:'--, alive, 214 days
676.0
TCGA-02-0055-01A
0 years, female, white, stage:'--, dead, 76 days
636.4
TCGA-76-4925-01A
0 years, male, white, stage:'--, dead, 146 days
619.0
TCGA-76-4932-01A
0 years, female, white, stage:'--, dead, 1458 days
612.8
TCGA-14-1823-01A
0 years, female, white, stage:'--, dead, 543 days
593.4
TCGA-28-5218-01A
0 years, male, white, stage:'--, dead, 157 days
587.8
TCGA-12-5295-01A
0 years, female, white, stage:'--, dead, 454 days
585.5
TCGA-06-5408-01A
0 years, female, white, stage:'--, dead, 357 days
579.3
TCGA-27-2528-01A
0 years, male, white, stage:'--, dead, 480 days
569.6
TCGA-28-5207-01A
0 years, male, white, stage:'--, dead, 343 days
546.2
TCGA-06-2570-01A
0 years, female, white, stage:'--, alive, 958 days
544.0
TCGA-02-2485-01A
0 years, male, black or african american, stage:'--, alive, 470 days
543.8
TCGA-28-2509-01A
0 years, female, white, stage:'--, alive, 145 days
539.9
TCGA-06-5856-01A
0 years, male, white, stage:'--, dead, 114 days
537.5
TCGA-14-0817-01A
0 years, female, white, stage:'--, dead, 164 days
527.8
TCGA-06-0644-01A
0 years, male, black or african american, stage:'--, dead, 384 days
522.8
TCGA-26-1442-01A
0 years, male, white, stage:'--, alive, 953 days
517.9
TCGA-06-5416-01A
0 years, female, white, stage:'--, alive, 204 days
516.0
TCGA-02-2486-01A
0 years, male, white, stage:'--, dead, 618 days
513.4
TCGA-14-1825-01A
0 years, male, white, stage:'--, dead, 232 days
510.6
TCGA-06-2559-01A
0 years, male, white, stage:'--, dead, 150 days
508.3
TCGA-27-2523-01A
0 years, male, white, stage:'--, dead, 489 days
495.4
TCGA-12-0618-01A
0 years, male, white, stage:'--, dead, 395 days
489.3
TCGA-12-5299-01A
0 years, female, white, stage:'--, dead, 98 days
487.1
TCGA-14-1034-01A
0 years, female, stage:'--, dead, 485 days
486.8
TCGA-06-0174-01A
0 years, male, white, stage:'--, dead, 98 days
485.5
TCGA-06-0130-01A
0 years, male, white, stage:'--, dead, 394 days
482.1
TCGA-14-0789-01A
0 years, male, white, stage:'--, dead, 342 days
479.8
TCGA-06-2558-01A
0 years, female, white, stage:'--, dead, 380 days
478.6
TCGA-06-0210-01A
0 years, female, white, stage:'--, dead, 225 days
473.8
TCGA-28-5209-01A
0 years, female, white, stage:'--, alive, 442 days
473.7
TCGA-12-3653-01A
0 years, female, white, stage:'--, dead, 442 days
472.7
TCGA-06-0686-01A
0 years, male, white, stage:'--, dead, 432 days
470.6
TCGA-06-5412-01A
0 years, female, white, stage:'--, dead, 138 days
469.3
TCGA-14-2554-01A
0 years, female, white, stage:'--, dead, 532 days
465.9
TCGA-12-0619-01A
0 years, male, white, stage:'--, dead, 1062 days
464.4
TCGA-06-0129-01A
0 years, male, asian, stage:'--, dead, 1024 days
464.0
TCGA-06-5858-01A
0 years, female, white, stage:'--, alive, 187 days
462.6
TCGA-28-5208-01A
0 years, male, white, stage:'--, dead, 544 days
462.6
TCGA-28-5215-01A
0 years, female, white, stage:'--, dead, 335 days
461.6
TCGA-06-5413-01A
0 years, male, white, stage:'--, alive, 268 days
455.3
TCGA-26-5132-01A
0 years, male, white, stage:'--, alive, 286 days
455.2
TCGA-06-2563-01A
0 years, female, white, stage:'--, alive, 932 days
453.8
TCGA-27-1830-01A
0 years, male, white, stage:'--, dead, 154 days
453.1
TCGA-19-1390-01A
0 years, female, white, stage:'--, dead, 772 days
451.4
TCGA-28-5204-01A
0 years, male, white, stage:'--, dead, 454 days
451.3
TCGA-12-0616-01A
0 years, female, white, stage:'--, dead, 448 days
451.2
TCGA-06-2557-01A
0 years, male, black or african american, stage:'--, dead, 33 days
449.2
TCGA-06-0139-01A
0 years, male, white, stage:'--, dead, 362 days
445.7
TCGA-06-2565-01A
0 years, male, asian, stage:'--, dead, 506 days
444.7
TCGA-12-3652-01A
0 years, male, white, stage:'--, dead, 1062 days
439.4
TCGA-27-2519-01A
0 years, male, white, stage:'--, dead, 550 days
436.4
TCGA-26-5139-01A
0 years, female, white, stage:'--, alive, 48 days
435.0
TCGA-06-0238-01A
0 years, male, white, stage:'--, dead, 405 days
434.0
TCGA-19-2620-01A
0 years, male, white, stage:'--, dead, 148 days
431.5
TCGA-76-4931-01A
0 years, female, white, stage:'--, dead, 279 days
426.1
TCGA-06-5418-01A
0 years, female, white, stage:'--, dead, 83 days
422.3
TCGA-06-0190-01A
0 years, male, white, stage:'--, dead, 317 days
422.1
TCGA-32-2615-01A
0 years, male, white, stage:'--, dead, 485 days
421.2
TCGA-26-5135-01A
0 years, female, white, stage:'--, dead, 270 days
419.2
TCGA-06-5410-01A
0 years, female, white, stage:'--, dead, 108 days
418.4
TCGA-32-1980-01A
0 years, male, white, stage:'--, dead, 36 days
414.8
TCGA-27-2526-01A
0 years, female, white, stage:'--, dead, 87 days
414.6
TCGA-06-2567-01A
0 years, male, white, stage:'--, dead, 133 days
414.2
TCGA-27-1834-01A
0 years, male, white, stage:'--, dead, 1233 days
413.4
TCGA-41-2571-01A
0 years, male, white, stage:'--, dead, 26 days
411.0
TCGA-28-1753-01A
0 years, male, white, stage:'--, alive, 37 days
410.3
TCGA-19-2629-01A
0 years, male, white, stage:'--, dead, 737 days
407.5
TCGA-19-2625-01A
0 years, female, white, stage:'--, dead, 124 days
402.5
TCGA-06-2564-01A
0 years, male, white, stage:'--, alive, 181 days
392.7
TCGA-06-0744-01A
0 years, male, white, stage:'--, dead, 1426 days
391.7
TCGA-06-0645-01A
0 years, female, white, stage:'--, dead, 175 days
390.2
TCGA-15-1444-01A
0 years, male, white, stage:'--, dead, 1537 days
390.2
TCGA-32-1970-01A
0 years, male, white, stage:'--, dead, 468 days
389.0
TCGA-76-4929-01A
0 years, female, white, stage:'--, dead, 111 days
384.1
TCGA-41-3915-01A
0 years, male, white, stage:'--, dead, 360 days
377.8
TCGA-12-3650-01A
0 years, male, white, stage:'--, dead, 333 days
376.5
TCGA-15-0742-01A
0 years, male, white, stage:'--, dead, 419 days
374.4
TCGA-06-0187-01A
0 years, male, white, stage:'--, dead, 828 days
374.1
TCGA-06-0156-01A
0 years, male, white, stage:'--, dead, 178 days
372.2
TCGA-28-5220-01A
0 years, male, white, stage:'--, dead, 388 days
371.8
TCGA-32-2616-01A
0 years, female, white, stage:'--, dead, 224 days
371.6
TCGA-06-0125-01A
0 years, female, white, stage:'--, dead, 1448 days
365.7
TCGA-06-0178-01A
0 years, male, white, stage:'--, dead, 2681 days
364.8
TCGA-28-2514-01A
0 years, male, asian, stage:'--, alive, 160 days
364.2
TCGA-19-2624-01A
0 years, male, white, stage:'--, dead, 5 days
361.2
TCGA-32-1982-01A
0 years, female, white, stage:'--, dead, 142 days
359.8
TCGA-06-0138-01A
0 years, male, white, stage:'--, dead, 737 days
358.5
TCGA-28-2513-01A
0 years, female, white, stage:'--, alive, 222 days
354.4
TCGA-27-1835-01A
0 years, female, white, stage:'--, dead, 648 days
353.4
TCGA-32-2632-01A
0 years, male, white, stage:'--, dead, 269 days
352.6
TCGA-06-0882-01A
0 years, male, white, stage:'--, dead, 632 days
348.9
TCGA-27-1837-01A
0 years, male, white, stage:'--, dead, 427 days
348.7
TCGA-32-2634-01A
0 years, male, white, stage:'--, alive, 693 days
347.4
TCGA-06-2561-01A
0 years, female, white, stage:'--, dead, 537 days
340.0
TCGA-06-0749-01A
0 years, male, black or african american, stage:'--, dead, 82 days
337.5
TCGA-06-0141-01A
0 years, male, white, stage:'--, dead, 313 days
337.1
TCGA-27-2521-01A
0 years, male, white, stage:'--, dead, 510 days
336.5
TCGA-06-0211-01A
0 years, male, white, stage:'--, dead, 360 days
336.0
TCGA-16-0846-01A
0 years, male, white, stage:'--, dead, 119 days
335.6
TCGA-76-4927-01A
0 years, male, white, stage:'--, dead, 535 days
335.4
TCGA-06-5411-01A
0 years, male, white, stage:'--, dead, 254 days
333.4
TCGA-06-0750-01A
0 years, male, white, stage:'--, dead, 28 days
325.5
TCGA-06-0646-01A
0 years, male, white, stage:'--, dead, 175 days
318.9
TCGA-27-1831-01A
0 years, male, white, stage:'--, dead, 505 days
314.7
TCGA-06-0132-01A
0 years, male, white, stage:'--, dead, 771 days
307.4
TCGA-27-1832-01A
0 years, female, white, stage:'--, dead, 300 days
306.0
TCGA-32-5222-01A
0 years, male, white, stage:'--, dead, 585 days
299.4
TCGA-41-4097-01A
0 years, female, white, stage:'--, dead, 6 days
297.1
TCGA-06-0168-01A
0 years, female, white, stage:'--, dead, 598 days
293.2
TCGA-06-0157-01A
0 years, female, white, stage:'--, dead, 97 days
292.3
TCGA-27-2524-01A
0 years, male, white, stage:'--, dead, 231 days
291.7
TCGA-06-0878-01A
0 years, male, white, stage:'--, alive, 218 days
290.7
TCGA-12-0821-01A
0 years, male, white, stage:'--, dead, 323 days
287.0
TCGA-14-0787-01A
0 years, male, asian, stage:'--, dead, 68 days
276.4
TCGA-19-2619-01A
0 years, female, black or african american, stage:'--, alive, 294 days
274.1
TCGA-32-2638-01A
0 years, male, white, stage:'--, dead, 766 days
268.3
TCGA-06-0745-01A
0 years, male, white, stage:'--, dead, 239 days
267.8
TCGA-06-0184-01A
0 years, male, white, stage:'--, dead, 2126 days
265.9
TCGA-06-2562-01A
0 years, male, white, stage:'--, dead, 382 days
258.9
TCGA-08-0386-01A
0 years, male, white, stage:'--, dead, 548 days
256.6
TCGA-32-4213-01A
0 years, female, white, stage:'--, alive, 604 days
248.7
TCGA-06-5414-01A
0 years, male, white, stage:'--, alive, 273 days
240.8
TCGA-14-1829-01A
0 years, male, black or african american, stage:'--, alive, 218 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
RPL22 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
33.5
Number of samples
58
Samples
Sample
Description
TPM
AK043
N, NA, stage:NA, alive, 660 days
82.2
AK142
N, NA, stage:NA, alive, 90 days
66.7
AK066
N, NA, stage:NA, alive, 960 days
66.3
AK156
N, NA, stage:NA, dead, 330 days
65.9
AK124
N, NA, stage:NA, alive, 1920 days
52.1
AK205
N, NA, stage:NA, dead, 120 days
49.6
AK133
N, NA, stage:NA, dead, 360 days
48.6
AK103
N, NA, stage:NA, alive, 1320 days
45.1
AK041
N, NA, stage:NA, alive, 810 days
44.6
AK231
N, NA, stage:NA, dead, 240 days
44.1
AK051
N, NA, stage:NA, dead, 360 days
43.2
AK117
N, NA, stage:NA, dead, 210 days
41.7
AK081
N, NA, stage:NA, dead, 180 days
40.9
AK074
N, NA, stage:NA, alive, 300 days
40.8
AK085
N, NA, stage:NA, alive, 660 days
38.7
AK213
N, NA, stage:NA, alive, 2010 days
38.3
AK173
N, NA, stage:NA, dead, 180 days
38.1
AK165
N, NA, stage:NA, alive, 360 days
36.2
AK227
N, NA, stage:NA, alive, 300 days
35.8
AK236
N, NA, stage:NA, dead, 360 days
34.8
AK188
N, NA, stage:NA, alive, 420 days
33.4
AK098
N, NA, stage:NA, dead, 660 days
32.9
AK102
N, NA, stage:NA, alive, 1740 days
32.3
AK055
N, NA, stage:NA, dead, 240 days
32.1
AK158
N, NA, stage:NA, dead, 360 days
32.0
AK178
N, NA, stage:NA, dead, 240 days
31.4
AK199
N, NA, stage:NA, alive, 1860 days
31.3
AK072
N, NA, stage:NA, dead, 150 days
30.6
AK218
N, NA, stage:NA, dead, 180 days
30.2
AK015
N, NA, stage:NA, alive, 720 days
29.5
AK003
N, NA, stage:NA, dead, 600 days
28.9
AK195
N, NA, stage:NA, dead, 390 days
28.8
AK049
N, NA, stage:NA, dead, 180 days
28.6
AK134
N, NA, stage:NA, dead, 360 days
28.4
AK071
N, NA, stage:NA, dead, 540 days
28.1
AK030
N, NA, stage:NA, dead, 120 days
28.0
AK099
N, NA, stage:NA, dead, 420 days
27.9
AK185
N, NA, stage:NA, alive, 330 days
27.7
AK079
N, NA, stage:NA, dead, 210 days
27.5
AK123
N, NA, stage:NA, dead, 180 days
27.3
AK089
N, NA, stage:NA, dead, 330 days
26.1
AK002
N, NA, stage:NA, dead, 570 days
26.0
AK053
N, NA, stage:NA, dead, 300 days
26.0
AK100
N, NA, stage:NA, alive, 960 days
25.2
AK091
N, NA, stage:NA, dead, 210 days
24.6
AK183
N, NA, stage:NA, alive, 360 days
24.5
AK167
N, NA, stage:NA, dead, 180 days
24.4
AK139
N, NA, stage:NA, dead, 270 days
24.4
AK068
N, NA, stage:NA, alive, 360 days
23.1
AK153
N, NA, stage:NA, dead, 240 days
22.5
AK006
N, NA, stage:NA, dead, 360 days
22.3
AK149
N, NA, stage:NA, dead, 420 days
21.8
AK076
N, NA, stage:NA, alive, 660 days
21.5
AK005
N, NA, stage:NA, dead, 240 days
21.0
AK035
N, NA, stage:NA, dead, 210 days
18.2
AK216
N, NA, stage:NA, dead, 360 days
16.1
AK088
N, NA, stage:NA, dead, 360 days
15.0
AK226
N, NA, stage:NA, dead, 360 days
14.5
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0206230003
Tumor
1.0
CPT0217000004
Tumor
1.0
CPT0218330004
Tumor
0.9
CPT0219080004
Tumor
0.9
CPT0218690004
Tumor
0.8
CPT0162020003
Tumor
0.7
CPT0189460003
Tumor
0.6
CPT0207030003
Tumor
0.6
CPT0087730003
Tumor
0.6
CPT0206560003
Tumor
0.5
CPT0205450004
Tumor
0.5
CPT0162100003
Tumor
0.5
CPT0206110003
Tumor
0.5
CPT0168380003
Tumor
0.5
CPT0002410011
Tumor
0.5
CPT0087570003
Tumor
0.4
CPT0161730003
Tumor
0.4
CPT0182580003
Tumor
0.4
CPT0216920008
Tumor
0.4
CPT0206670004
Tumor
0.4
CPT0127480003
Tumor
0.4
CPT0208980003
Tumor
0.4
CPT0205570003
Tumor
0.4
CPT0125570003
Tumor
0.4
CPT0175060003
Tumor
0.3
CPT0224540004
Tumor
0.3
CPT0127420003
Tumor
0.3
CPT0189650004
Tumor
0.3
CPT0206880003
Tumor
0.3
CPT0087950003
Tumor
0.3
CPT0093360003
Tumor
0.3
CPT0190240004
Tumor
0.3
CPT0221180003
Tumor
0.2
CPT0167860004
Tumor
0.2
CPT0228220003
Tumor
0.2
CPT0217430008
Tumor
0.2
CPT0205670004
Tumor
0.2
CPT0204410003
Normal
0.2
CPT0089150003
Tumor
0.2
CPT0182500003
Tumor
0.2
CPT0204330003
Normal
0.2
CPT0186100003
Tumor
0.2
CPT0125220003
Tumor
0.2
CPT0168080003
Tumor
0.1
CPT0207090003
Tumor
0.1
CPT0078580003
Tumor
0.1
CPT0206450003
Tumor
0.1
CPT0093450003
Tumor
0.1
CPT0064650003
Tumor
0.1
CPT0217710008
Tumor
0.1
CPT0204380003
Normal
0.1
CPT0218830004
Tumor
0.1
CPT0190360004
Tumor
0.1
CPT0218770003
Tumor
0.1
CPT0168590003
Tumor
0.1
CPT0123530003
Tumor
0.1
CPT0217060003
Tumor
0.0
CPT0189570004
Tumor
0.0
CPT0104220003
Tumor
0.0
CPT0167750004
Tumor
0.0
CPT0217190003
Tumor
0.0
CPT0206000004
Tumor
0.0
CPT0204370003
Normal
0.0
CPT0167640003
Tumor
0.0
CPT0093510003
Tumor
0.0
CPT0196850003
Tumor
0.0
CPT0167530003
Tumor
-0.1
CPT0205780003
Tumor
-0.1
CPT0071100003
Tumor
-0.1
CPT0168830003
Tumor
-0.1
CPT0204350003
Normal
-0.1
CPT0064890003
Tumor
-0.1
CPT0092440003
Tumor
-0.1
CPT0218890004
Tumor
-0.1
CPT0206780003
Tumor
-0.1
CPT0201710003
Tumor
-0.1
CPT0168270003
Tumor
-0.1
CPT0093550003
Tumor
-0.1
CPT0125510003
Tumor
-0.1
CPT0168720003
Tumor
-0.2
CPT0189750004
Tumor
-0.2
CPT0217100003
Tumor
-0.2
CPT0217880003
Tumor
-0.2
CPT0189850004
Tumor
-0.2
CPT0167970003
Tumor
-0.2
CPT0225730003
Tumor
-0.2
CPT0204360003
Normal
-0.2
CPT0171580008
Tumor
-0.2
CPT0224390004
Tumor
-0.2
CPT0079790003
Tumor
-0.2
CPT0204420003
Normal
-0.2
CPT0204340003
Normal
-0.3
CPT0204390003
Normal
-0.3
CPT0189250003
Tumor
-0.3
CPT0205890003
Tumor
-0.3
CPT0225760003
Tumor
-0.3
CPT0087680003
Tumor
-0.3
CPT0182550003
Tumor
-0.4
CPT0104330003
Tumor
-0.4
CPT0218670003
Tumor
-0.4
CPT0224600003
Tumor
-0.4
CPT0204400003
Normal
-0.4
CPT0168480003
Tumor
-0.4
CPT0224330003
Tumor
-0.5
CPT0218960004
Tumor
-0.5
CPT0206330003
Tumor
-0.6
CPT0162140003
Tumor
-0.6
CPT0093590003
Tumor
-0.6
CPT0199770003
Tumor
-0.6
CPT0209440003
Tumor
-0.7
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.